問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
未分科
下載
2022-11-01 - 2025-01-07
Condition/Disease
Test Drug
Participate Sites8Sites
Not yet recruiting8Sites
2022-11-01 - 2025-04-14
Participate Sites9Sites
2022-09-01 - 2026-12-31
Participate Sites7Sites
Recruiting7Sites
2022-07-01 - 2028-05-31
Participate Sites5Sites
Recruiting5Sites
2020-04-01 - 2025-11-26
Not yet recruiting2Sites
Recruiting4Sites
Terminated1Sites
2022-01-01 - 2026-03-31
Participate Sites6Sites
Terminated2Sites
2016-11-01 - 2025-12-31
Participate Sites12Sites
Terminated11Sites
Division of Hematology & Oncology
2014-02-01 - 2016-01-31
Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset
Ticagrelor
Participate Sites11Sites
Terminated10Sites
Study ended1Sites
Division of Neurology
2018-07-24 - 2021-01-05
Advanced Solid Tumors
ABBV-428
Participate Sites2Sites
2017-01-05 - 2019-12-31
Solid Tumors
TECENTRIQ
全部
